Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) is projected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Abeona Therapeutics to post earnings of ($0.33) per share and revenue of $4.5720 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, March 17th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.01. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $5.65 million. On average, analysts expect Abeona Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Abeona Therapeutics Stock Down 0.7%

Abeona Therapeutics stock opened at $5.86 on Tuesday. The firm has a 50 day simple moving average of $5.04 and a 200 day simple moving average of $5.04. The company has a current ratio of 6.93, a quick ratio of 6.74 and a debt-to-equity ratio of 0.05. Abeona Therapeutics has a 1-year low of $4.00 and a 1-year high of $7.54. The firm has a market capitalization of $333.32 million, a price-to-earnings ratio of 5.69 and a beta of 1.35.

Insider Activity at Abeona Therapeutics

In other news, insider Madhav Vasanthavada sold 5,548 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $5.96, for a total transaction of $33,066.08. Following the transaction, the insider directly owned 313,071 shares in the company, valued at approximately $1,865,903.16. This represents a 1.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.40% of the company’s stock.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC grew its holdings in shares of Abeona Therapeutics by 59.4% during the 4th quarter. Barclays PLC now owns 99,311 shares of the biopharmaceutical company’s stock valued at $523,000 after purchasing an additional 37,014 shares during the last quarter. Jump Financial LLC bought a new position in shares of Abeona Therapeutics during the 4th quarter valued at $400,000. Rhumbline Advisers grew its holdings in shares of Abeona Therapeutics by 3,541.0% during the 2nd quarter. Rhumbline Advisers now owns 67,505 shares of the biopharmaceutical company’s stock valued at $383,000 after purchasing an additional 65,651 shares during the last quarter. LPL Financial LLC grew its holdings in shares of Abeona Therapeutics by 5.3% during the 4th quarter. LPL Financial LLC now owns 62,873 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 3,165 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Abeona Therapeutics by 25.4% during the 4th quarter. XTX Topco Ltd now owns 49,338 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 9,979 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on ABEO shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday, January 21st. Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a report on Monday, March 9th. Stifel Nicolaus set a $17.00 price target on shares of Abeona Therapeutics in a report on Tuesday, March 17th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, March 19th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.